Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Locus Pharmaceuticals Inc.

www.locuspharmaceuticals.com

Latest From Locus Pharmaceuticals Inc.

Ansaris elects Cashman to board

Ansaris, a structure-based drug discovery company and division of Locus Pharmaceuticals, has elected Christopher Cashman to its board of directors. He was previously CEO of Protez Pharmaceuticals and Message Pharmaceuticals and global director of business and new development for Pfizer. Mr Cashman is also on the boards of JDP Therapeutics, Noble Biomaterials and MBF Therapeutics.

New chief scientific officer at Viamet

Dr William Moore has joined Viamet Pharmaceuticals, a US company developing metalloenzyme inhibitors, as chief scientific officer. Dr Moore has 21 years' R&D experience, primarily in early-stage companies. He was formerly chief scientific officer and vice-president of R&D at Locus Pharmaceuticals. Before that, he worked at Axys Pharmaceuticals as vice-president of target discovery and validation.

Companies

BioLeap LLC

BioLeap LLC hopes to be part of the solution to Big Pharma's pipeline problem. Its computational technology for identifying and optimizing lead compounds focuses on the free energy of binding, which represents an enormous computational problem. But the developers of BioLeap's technology have created an industrial process that makes such calculations feasible in a reasonably fast time frame.
BioPharmaceutical

Silicos NV

Silicos NV's computational lead identification and development platform combines proprietary and commercial computational chemistry tools, and has potential in many indications such as cancer and infectious diseases, central nervous system disorders, and immunodeficiency diseases. The company is using its virtual fragment-based tools to create small molecules for both clients and for its own internal projects.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Locus Discovery Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Locus Pharmaceuticals Inc.
  • Senior Management
  • H. Joseph Reiser, PhD, Pres. & CEO
    James L Bergey, PhD, VP, Bus. Dev.
  • Contact Info
  • Locus Pharmaceuticals Inc.
    Phone: (215) 358-2000
    512 Township Line Rd.
    4 Valley Sq.
    Blue Bell, PA 19422
    USA
UsernamePublicRestriction

Register